Skip to main content

Table 1 Treatment regimen for a heavily pretreated patient with diffuse large B-cell lymphoma

From: Single-agent MOR208 salvage and maintenance therapy in a patient with refractory/relapsing diffuse large B-cell lymphoma: a case report

First-line treatment

 R-CHOP × 8 intravenously plus liposomal cytarabine (DepoCyte) intrathecally

Rituximab 375 mg/m2 (D1) Cyclophosphamide 750 mg/m2 (D1) Doxorubicin 50 mg/m2 (D1) Vincristine 1.4 mg/m2 (D1) Prednisone 40 mg/m2/day (D1–D5) Liposomal cytarabine (cycles 1–4)

Second-line treatment

 R-ESHAP × 3

Rituximab 375 mg/m2 (D1) Etoposide 40 mg/m2/day (D1–D4) Methylprednisolone 500 mg/m2/day (D1–D4) Cisplatin 25 mg/m2/day (D1–D4) Cytarabine 2000 mg/m2 (D5)

 DexaBEAM

Dexamethasone 24 mg/day (D1–D10) Carmustine 60 mg/m2 (D2) Etoposide 200 mg/m2/day (D4–D7) Cytarabine 100 mg/m2/day (D4–D7) Melphalan 20 mg/m2 (D3)

 Z-BEAM-conditioned autologous stem cell transplant

Rituximab 205 mg/m2, followed by ibritumomab tiuxetan 32.0 mCi (1184 MBq) (D1) Carmustine 60 mg/m2 (D8) Etoposide 200 mg/m2/day (D10–D13) Cytarabine 100 mg/m2/day (D10–D13) Melphalan 20 mg/m2 (D9)

Third-line treatment

 Clinical trial

Induction: MOR208 12 mg/kg for 12 weekly doses Maintenance: MOR208 12 mg/kg every second week

  1. D, treatment day
Back to article page

Journal of Medical Case Reports

ISSN: 1752-1947